-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Pharmaceutical Guanlan
On July 6, Sirnaomics announced that the company's small interfering nucleic acid (siRNA) candidate STP707 clinical trial application has been approved by the US FDA
RNA interference (RNAi) is a method of silencing genes through double-stranded RNA
According to the press release, STP707 is a siRNA drug with both anti-tumor and anti-fibrosis effects.
The overexpression of TGF-β1 and COX-2 play a key regulatory role in tumor formation
Previously, STP707 has been in preclinical non-human primate studies.
Note: The original text has been deleted
Reference materials:
[1] The RNAi drug candidate STP707 from Sinopharm was approved by the FDA for the phase I clinical IND for the treatment of solid tumors.